Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million.
Risdiplam, to be marketed by Roche, is an investigational, orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA). SMA is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common genetic cause of infant mortality and one of the most common rare diseases, affecting approximately one in 11,000 babies.
Wilmer Hale acted as legal advisor to PTC Therapeutics on the transaction. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma.
This text is a press release from Royalty Pharma. The full text version of the article can be found here: https://www.royaltypharma.com/news-releases/news-release-details/royalty-pharma-acquires-royalty-interest-risdiplam-ptc